{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:57Z","timestamp":1792790577366,"version":"4.5.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>A phase 2, international, open-label, nonrandomized, single-arm trial was conducted to evaluate the efficacy and safety of tipifarnib, a farnesyltransferase inhibitor, as monotherapy for relapsed\/refractory peripheral T-cell lymphoma (PTCL) and to evaluate tumor mutation profile as a biomarker of response. Adults with relapsed\/refractory PTCL received tipifarnib 300\u00a0mg orally twice daily for 21\u00a0days in a 28-day cycle. The primary end point was objective response rate (ORR); secondary end points included ORR, progression-free survival (PFS), duration of response (DOR), and adverse events (AEs) in specific subtypes. Sixty-five patients with PTCL were enrolled: n\u00a0=\u00a038 angioimmunoblastic T-cell lymphoma (AITL), n\u00a0=\u00a025 PTCL not otherwise specified, and n\u00a0=\u00a02 other T-cell lymphomas. The ORR was 39.7% (95% confidence interval [CI], 28.1-52.5) in all patients and 56.3% (95%\u00a0CI, 39.3-71.8) for AITL. Median PFS was 3.5\u00a0months overall (954%\u00a0CI, 2.1-4.4), and 3.6\u00a0months (95%\u00a0CI, 1.9-8.3) for AITL. Median DOR was 3.7\u00a0months (95%\u00a0CI, 2.0-15.3), and greatest in patients with AITL (7.8\u00a0months; 95%\u00a0CI, 2.0-16.3). The median overall survival was 32.8\u00a0months (95%\u00a0CI, 14.4 to not applicable). Tipifarnib-related hematologic AEs were manageable and included neutropenia (43.1%), thrombocytopenia (36.9%), and anemia (30.8%); other tipifarnib-related AEs included nausea (29.2%) and diarrhea (27.7%). One treatment-related death occurred. Mutations in RhoA, DNMT3A, and IDH2 were seen in 60%, 33%, and 27%, respectively, in the AITL tipifarnib responder group vs 36%, 9%, and 9% in the nonresponder group. Tipifarnib monotherapy demonstrated encouraging clinical activity in heavily pretreated relapsed\/refractory PTCL, especially in AITL, with a manageable safety profile. This trial was registered at www.ClinicalTrials.gov as #NCT02464228.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012806","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T19:03:02Z","timestamp":1720724582000},"page":"4581-4592","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas","family":"Witzig","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"de la Cruz Vicente","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Mart\u00edn Garc\u00eda-Sancho","sequence":"additional","affiliation":[{"name":"5Hematology Department, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n Biom\u00e9dica en Red - C\u00e1ncer (CIBERONC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"6Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Roncero Vidal","sequence":"additional","affiliation":[{"name":"7Servei Hematologia ICO Girona, Hospital Universitari de Girona Dr Josep Trueta, Catalunya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"de O\u00f1a Navarrete","sequence":"additional","affiliation":[{"name":"8Hematology Department, MD Anderson Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mar\u00edn-Niebla","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Vall D\u2019Hebron Institute of Oncology, Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Rodriguez Izquierdo","sequence":"additional","affiliation":[{"name":"10Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9467-932X","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Terol","sequence":"additional","affiliation":[{"name":"11Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[{"name":"12Hematology Department, Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Saunders","sequence":"additional","affiliation":[{"name":"13Kura Oncology Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Bendris","sequence":"additional","affiliation":[{"name":"13Kura Oncology Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mackey","sequence":"additional","affiliation":[{"name":"13Kura Oncology Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"Leoni","sequence":"additional","affiliation":[{"name":"13Kura Oncology Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-3162","authenticated-orcid":false,"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"2","key":"2024091012553579000_bib1","first-page":"267","article-title":"Advances and personalized approaches in the frontline treatment of T-cell lymphomas","volume":"12","author":"Angelos","year":"2022","journal-title":"J\u00a0Pers Med"},{"issue":"9","key":"2024091012553579000_bib2","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"issue":"20","key":"2024091012553579000_bib3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2024091012553579000_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2024091012553579000_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"22","key":"2024091012553579000_bib6","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.18632\/oncotarget.24592","article-title":"Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features","volume":"9","author":"Manso","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"2024091012553579000_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOH.0000000000000261","article-title":"The curious origins of angioimmunoblastic T-cell lymphoma","volume":"23","author":"Cort\u00e9s","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2024091012553579000_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"3","key":"2024091012553579000_bib9","first-page":"410","article-title":"Genetic landscape of peripheral T-cell lymphoma","volume":"12","author":"Hathuc","year":"2022","journal-title":"Life (Basel)"},{"issue":"1","key":"2024091012553579000_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024091012553579000_bib11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2024091012553579000_bib12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2020009655","article-title":"Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024091012553579000_bib13","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"10","key":"2024091012553579000_bib14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"2024091012553579000_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2024091012553579000_bib16","first-page":"303","article-title":"Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib","volume":"6","author":"Martinelli","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"2024091012553579000_bib17","doi-asserted-by":"publisher","DOI":"10.4137\/CMT.S1097","article-title":"Pharmacotherapy of hematologic malignancies with tipifarnib","volume":"1","author":"Kotsianidis","year":"2009","journal-title":"Clin Med. Therapeutics"},{"issue":"9","key":"2024091012553579000_bib18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","article-title":"Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas","volume":"19","author":"Gilardi","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2024091012553579000_bib19","author":"Ho","year":"29-31  2020"},{"issue":"11","key":"2024091012553579000_bib20","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2024091012553579000_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/MCB.20.1.139-148.2000","article-title":"The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis","volume":"20","author":"Jiang","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2024091012553579000_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/erc.0.0110191","article-title":"Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?","volume":"11","author":"O'Regan","year":"2004","journal-title":"Endocr Relat Cancer"},{"issue":"21","key":"2024091012553579000_bib23","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.3390\/cancers13215310","article-title":"Potential of farnesyl transferase inhibitors in combination regimens in squamous cell carcinomas","volume":"13","author":"Kessler","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2024091012553579000_bib24","first-page":"5656","article-title":"Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations","volume":"63","author":"Brunner","year":"2003","journal-title":"Cancer Res"},{"issue":"6","key":"2024091012553579000_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41557-019-0237-6","article-title":"Dual chemical probes enable quantitative system-wide analysis of protein prenylation and prenylation dynamics","volume":"11","author":"Storck","year":"2019","journal-title":"Nat Chem"},{"issue":"1","key":"2024091012553579000_bib26","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1038\/s41598-020-63434-5","article-title":"Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma","volume":"10","author":"Alonso-Alonso","year":"2020","journal-title":"Sci Rep"},{"issue":"18","key":"2024091012553579000_bib27","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood"},{"issue":"27","key":"2024091012553579000_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024091012553579000_bib29","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1200\/JCO.2004.03.200","article-title":"Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies","volume":"22","author":"Zimmerman","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024091012553579000_bib30","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/leu.2011.124","article-title":"A\u00a0phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia","volume":"25","author":"Kirschbaum","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2024091012553579000_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00001813-200503000-00011","article-title":"Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial","volume":"16","author":"Lara","year":"2005","journal-title":"Anticancer Drugs"},{"issue":"9","key":"2024091012553579000_bib32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A\u00a0targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2024091012553579000_bib33","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2024091012553579000_bib34","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41598-021-83352-4","article-title":"Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma","volume":"11","author":"Jones","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"2024091012553579000_bib35","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Coiffier","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"2024091012553579000_bib36","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"2024091012553579000_bib37","volume-title":"BELEODAQ\u00ae (belinostat) for injection, for intravenous use. Prescribing information","year":"2022"},{"issue":"9","key":"2024091012553579000_bib38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024091012553579000_bib39","first-page":"1108","article-title":"Update on recurrent mutations in angioimmunoblastic T-cell lymphoma","volume":"14","author":"Yu","year":"2021","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2024091012553579000_bib40","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-type-specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024091012553579000_bib41","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"2024091012553579000_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"2024091012553579000_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/cells8070646","article-title":"RHO family GTPases in the biology of lymphoma","volume":"8","author":"Voena","year":"2019","journal-title":"Cells"},{"issue":"9","key":"2024091012553579000_bib44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood"},{"issue":"18","key":"2024091012553579000_bib45","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1182\/blood-2011-02-334870","article-title":"Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation","volume":"118","author":"Ding","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2024091012553579000_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3324\/haematol.2013.087734","article-title":"Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells","volume":"99","author":"Ding","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"2024091012553579000_bib47","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"16","key":"2024091012553579000_bib48","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024091012553579000_bib49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024091012553579000_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.21.02463","article-title":"Moving beyond one size fits all for T-cell lymphoma","volume":"40","author":"Moskowitz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024091012553579000_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/cancers14010086","article-title":"CXCL12 in pancreatic cancer: its function and potential as a therapeutic drug target","volume":"14","author":"Malik","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4581\/2241269\/blooda_adv-2024-012806-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4581\/2241269\/blooda_adv-2024-012806-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:56:29Z","timestamp":1725972989000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4581\/516944\/Phase-2-trial-of-the-farnesyltransferase-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":51,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012806","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}